Keytruda is primarily used in treating various cancer types, including melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, stomach cancer, and urothelial carcinoma. Melanoma, specifically, is a type of skin cancer that originates in melanocytes, the cells responsible for producing melanin, the pigment giving skin its color. The medication is available through different payer types such as commercial, Medicare, and Medicaid, and distributed through various channels such as hospital pharmacies and specialty pharmacies.
The keytruda market research report is one of a series of new reports that provides keytruda market statistics, including keytruda industry global market size, regional shares, competitors with a keytruda market share, detailed keytruda market segments, market trends and opportunities, and any further data you may need to thrive in the keytruda industry. This keytruda market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The keytruda market size has grown strongly in recent years. It will grow from $19.71 billion in 2023 to $21.6 billion in 2024 at a compound annual growth rate (CAGR) of 9.6%. The growth observed in the historic period can be attributed to several factors, including improved patient outcomes, increased adoption of immunotherapy in cancer treatment, ongoing research and development efforts, enhanced patient compliance with treatments, and increased adoption of Keytruda (pembrolizumab) as a medication for cancer therapy.
The keytruda market size is expected to see strong growth in the next few years. It will grow to $31.52 billion in 2028 at a compound annual growth rate (CAGR) of 9.9%. The expected growth in the forecast period can be attributed to several factors, including expanding indications for Keytruda (pembrolizumab), emerging markets for cancer treatments, the increasing prevalence of cancer cases, rising healthcare expenditure globally, and the growing demand for precision medicine in oncology. Major trends anticipated during this period include a heightened demand for targeted therapies such as Keytruda, advancements in immunotherapy approaches, innovations in diagnostic technologies for cancer detection and monitoring, a surge in demand for effective cancer treatments, and ongoing advancements in cancer research.
The growth of the Keytruda market is expected to be propelled by the increasing prevalence of cancer. Cancer, a complex group of diseases characterized by abnormal cell growth and spread, is influenced by genetic, lifestyle, environmental, and hormonal factors. Keytruda (pembrolizumab) plays a crucial role in cancer treatment by leveraging the body's immune system to combat cancer cells more effectively. This represents a significant advancement in cancer treatment by harnessing immune system capabilities to target and attack cancer cells, offering new hope to patients with advanced or metastatic cancers. For example, according to the National Library of Medicine, the global cancer burden is projected to reach 28.4 million cases in 2040, marking a 47% increase from 2020. Thus, the rising prevalence of cancer is a driving force behind the Keytruda market.
Leading companies in the Keytruda market are focused on developing innovative products such as pembrolizumab to expand treatment options. Pembrolizumab, a monoclonal antibody medication belonging to immune checkpoint inhibitors, is marketed under the brand name Keytruda. It targets and inhibits a protein called PD-1 (programmed cell death protein 1) on immune cells known as T cells. For instance, in November 2023, Merck, a US-based pharmaceutical company, launched KEYTRUDA (pembrolizumab) in combination with fluoropyrimidine- and platinum-containing chemotherapy approved by the Food and Drug Administration (FDA). This combination therapy has shown significant improvements in overall survival and progression-free survival compared to chemotherapy alone, presenting a promising advancement in gastric cancer treatment. Clinical trials have demonstrated enhancements in overall survival (OS), progression-free survival (PFS), and overall response rate (ORR) compared to standalone chemotherapy.
In May 2024, CytomX Therapeutics, a US-based biotechnology company, partnered with Merck to assess CX-801 with KEYTRUDA (pembrolizumab) in patients with advanced metastatic solid tumors. This collaboration aims to evaluate the safety, tolerability, and preliminary efficacy of CX-801 in combination with KEYTRUDA for advanced metastatic solid tumors. Merck, a US-based company, offers Keytruda as part of its pharmaceutical portfolio.
Major companies operating in the keytruda market are Pfizer Inc., Johnson & Johnson Services Inc., Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Sanofi S.A., Novartis AG, AstraZeneca PLC, Bristol-Myers Squibb Company, Eli Lilly and Company, Amgen Inc., Gilead Sciences Inc., Teva Pharmaceutical Industries Ltd., Biogen Inc., Chugai Pharmaceutical Co. Ltd., BioNTech AG, Organon Co., Ono Pharmaceutical Co. Ltd., Samsung Bioepis Co. Ltd., Fate Therapeutics Inc., Merck Sharp & Dohme Corp., KinBio, Schering-Plough AB, LGM Pharma LLC, Gritstone Bio Inc.
North America was the largest region in the keytruda market in 2023. The regions covered in the keytruda market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the keytruda market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The keytruda market consists of sales of immunotherapy, combination therapies, clinical trials, and personalized medicine. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
Executive Summary
Keytruda Global Market Report 2024 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on keytruda market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
- Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
- Assess the Russia - Ukraine war’s impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
- Measure the impact of high global inflation on market growth.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for keytruda ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The keytruda market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.
- The impact of higher inflation in many countries and the resulting spike in interest rates.
- The continued but declining impact of COVID-19 on supply chains and consumption patterns.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Cancer Type: Melanoma; Lung Cancer; Head And Neck Cancer; Hodgkin Lymphoma; Stomach Cancer; Urothelial Carcinoma2) By Payer Type: Commercial; Medicare; Medicaid
3) By Distribution Channel: Hospital Pharmacies; Specialty Pharmacies
Key Companies Mentioned: Pfizer Inc.; Johnson & Johnson Services Inc.; Roche Holding AG; Merck & Co. Inc.; AbbVie Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- Pfizer Inc.
- Johnson & Johnson Services Inc.
- Roche Holding AG
- Merck & Co. Inc.
- AbbVie Inc.
- Sanofi S.A.
- Novartis AG
- AstraZeneca PLC
- Bristol-Myers Squibb Company
- Eli Lilly and Company
- Amgen Inc.
- Gilead Sciences Inc.
- Teva Pharmaceutical Industries Ltd.
- Biogen Inc.
- Chugai Pharmaceutical Co. Ltd.
- BioNTech AG
- Organon Co.
- Ono Pharmaceutical Co. Ltd.
- Samsung Bioepis Co. Ltd.
- Fate Therapeutics Inc.
- Merck Sharp & Dohme Corp.
- KinBio
- Schering-Plough AB
- LGM Pharma LLC
- Gritstone Bio Inc.
Methodology
LOADING...